Medical Journal of The Islamic Republic of Iran (MJIRI)
Iran University of Medical Sciences
Thu, Jul 11, 2024
[Archive]
Volume 33, Issue 1 (2-2019)
Med J Islam Repub Iran 2019 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ghaffari H, Navaser M, Mofid B, Mahdavi S R, Mohammadi R, Tavakol A. Fiducial markers in prostate cancer image-guided radiotherapy. Med J Islam Repub Iran 2019; 33 (1) :80-86
URL: http://mjiri.iums.ac.ir/article-1-5373-en.html
URL: http://mjiri.iums.ac.ir/article-1-5373-en.html
Hamed Ghaffari 
, Mahmoud Navaser , Bahram Mofid , Seied Rabi Mahdavi , Reza Mohammadi , Asieh Tavakol
, Mahmoud Navaser , Bahram Mofid , Seied Rabi Mahdavi , Reza Mohammadi , Asieh Tavakol
Department of Medical Physics & Student Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran , hamedghaffari@yahoo.com
Abstract: (3281 Views)
Background: Image-guided radiotherapy (IGRT) is recommended to reduce the risk of geometrical miss when modern radiotherapy technologies with high grades of conformity are used. The purpose of this study was to evaluate the efficacy of fiducial markers (FMs) for electronic portal imaging in prostate cancer radiotherapy in term of evaluating the complications associated with FMs implantation, quantifying inter-fraction prostate motion, and determination of optimal planning target volume (PTV) margins.
Methods: In this single institution, prospective, consecutive study, 27 patients underwent implantation of three-gold seed FMs into the prostate gland before prostate radiotherapy. Prior to computed tomography planning, all patients were asked to report any complication associated with FMs implantation that have experienced to date. Daily pre-treatment electronic portal images were captured, and prostate position errors were corrected if they were greater than 2 mm along three translational directions. Optimal PTV expansions were computed using van Herk formula [PTV-margin= 2.5Σ + 0.7σ].
Results: FMs implantation was successful with an acceptable toxicity profile in all patients. Without IGRT, margins of 5.4 mm, 5.8 mm and 5.5 mm, in vertical, longitudinal and lateral directions, respectively, are needed for a 95% confidence level of complete clinical target volume (CTV) coverage in each treatment session. The PTV margins of 3.0 mm, 3.3 mm and 4.0 mm in corresponding directions were calculated when FMs based electronic portal imaging was applied.
Conclusion: FMs based electronic portal imaging is an effective tool for prostate cancer IGRT.
Methods: In this single institution, prospective, consecutive study, 27 patients underwent implantation of three-gold seed FMs into the prostate gland before prostate radiotherapy. Prior to computed tomography planning, all patients were asked to report any complication associated with FMs implantation that have experienced to date. Daily pre-treatment electronic portal images were captured, and prostate position errors were corrected if they were greater than 2 mm along three translational directions. Optimal PTV expansions were computed using van Herk formula [PTV-margin= 2.5Σ + 0.7σ].
Results: FMs implantation was successful with an acceptable toxicity profile in all patients. Without IGRT, margins of 5.4 mm, 5.8 mm and 5.5 mm, in vertical, longitudinal and lateral directions, respectively, are needed for a 95% confidence level of complete clinical target volume (CTV) coverage in each treatment session. The PTV margins of 3.0 mm, 3.3 mm and 4.0 mm in corresponding directions were calculated when FMs based electronic portal imaging was applied.
Conclusion: FMs based electronic portal imaging is an effective tool for prostate cancer IGRT.
Type of Study: Original Research |
Subject:
Medical Physics and Radiation Therapy
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
